sPecam-1 quantification in samples from native, aseptic vs. septic (chronic vs. acute) revision surgeries. (A) Synovia samples were screened for their sPecam-1 content via Elisa, revealing significant differences between the groups according to their categorization to “septic (acute)”, “septic (chronic)”, “aseptic”, and “native”. We examined whether the marker differentiates between chronic and acute PJI. It was shown that the sPecam-1 quantities were not significantly different between chronic and acute PJI, but significantly higher for both groups compared to the aseptic, as well as to the native cohort. ***: p < 0.001 (very significant), **: p from 0.001 to 0.01 (very significant), n.s.: not significant (B) sPecam-1 as biomarker indicating PJI; ROC analysis with 95% confidence intervals was performed.